ProQR Therapeutics NV (STU:0PQ) Tariff Resilience Score: 5/10 (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0PQ ProQR Therapeutics NV STU:0PQ
51 GF Score
Price €1.51
GF Value €1.79
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is ProQR Therapeutics NV Tariff Resilience Score?

ProQR Therapeutics NV STU:0PQ -4.14% 51 Tariff Resilience Score is 5 as of Jul. 25, 2026. GuruFocus rates STU:0PQ with a GF Score™ of 51/100 and a GF Value™ of €1.79 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,370 Biotechnology companies, ProQR Therapeutics NV ranks better than 62.41% on this metric.

ProQR Therapeutics NV has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

ProQR Therapeutics NV has ProQR Therapeutics, based in the Netherlands, may face tariff risks due to its global supply chain for RNA therapies. However, its niche market and potential EU trade agreements offer some protection.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes ProQR Therapeutics NV might have Average Resilient.

ProQR Therapeutics NV  (STU:0PQ) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

ProQR Therapeutics NV Tariff Resilience Score Related Terms

STU:0PQ vs CRBP, NRXP, CRBU: Tariff Resilience Score Comparison

For the Biotechnology subindustry, ProQR Therapeutics NV's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProQR Therapeutics NV Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's Tariff Resilience Score falls into.


STU:0PQ
51GF Score
ProQR Therapeutics NV STU:0PQ
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
ProQR Therapeutics NV (STU:0PQ) has a Tariff Resilience Score of 5 as of Jul. 25, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, ProQR Therapeutics NV ranks #515 out of 1370 companies in the Biotechnology industry, placing it in the top 37.6%.
Is ProQR Therapeutics NV's Tariff Resilience Score too high?
ProQR Therapeutics NV's current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. ProQR Therapeutics NV's value of 5 is 25% above this industry median. Based on the distribution chart, ProQR Therapeutics NV ranks #515 out of 1370 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ProQR Therapeutics NV has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ProQR Therapeutics NV's Tariff Resilience Score compare to CRBP and NRXP?
According to the Biotechnology industry distribution chart, ProQR Therapeutics NV ranks #515 out of 1370 companies for Tariff Resilience Score. This puts ProQR Therapeutics NV in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. ProQR Therapeutics NV's value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProQR Therapeutics NV's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProQR Therapeutics NV's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProQR Therapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, ProQR Therapeutics NV (STU:0PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.79, compared to a current price of €1.51 — trading 15.9% below its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. ProQR Therapeutics NV's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For ProQR Therapeutics NV (STU:0PQ), the current Tariff Resilience Score is 5 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ProQR Therapeutics NV (STU:0PQ) Overvalued in 2026?

Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued. The current stock price of €1.51 is trading 15.9% below its estimated GF Value™ of €1.79. GuruFocus considers ProQR Therapeutics NV to be Modestly Undervalued.

Key valuation signals for STU:0PQ:

  • Tariff Resilience Score: 5
  • GF Value™: €1.79 vs. price of €1.51 (15.9% below fair value)
  • GF Score™: 51/100 with 4 warning signs
  • Industry Position: 25% above the Biotechnology median (#515 of 1370)

No single metric tells the full story. See the STU:0PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ProQR Therapeutics NV Business Description

Other Exchanges PRQR:USA
Address Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
51GF Score

Get the complete analysis for STU:0PQ

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.51
Price
€1.79
GF Value